Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli
- Address
- lock Available on a paid plan
Oncology and Hematology
At Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli, the strongest research activity is in neoplasms and hemic and lymphatic diseases, with many studies focused on common and hard-to-treat cancers such as non-small cell lung cancer, colorectal cancer, gastric cancer, and head and neck squamous cell carcinoma. These trials are designed to test new treatment options, compare them with current standards, and improve outcomes for patients with advanced or recurrent disease.
- Testing new cancer therapies for advanced solid tumors and metastatic disease
- Evaluating treatment effectiveness in lung, gastrointestinal, and head and neck cancers
- Studying personalized approaches for biomarker-selected tumors
The UOC Oncoematologia also participates in studies for blood cancers and related disorders, reflecting a broad oncology program with a strong translational focus.
Immunology and Autoimmune Diseases
A major part of the site’s portfolio covers immune system diseases and inflammatory conditions, including multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, juvenile idiopathic arthritis, and myasthenia gravis. These trials aim to better control disease activity, reduce relapses, and assess whether newer therapies can improve long-term management compared with established treatments.
- Exploring therapies for relapsing and progressive multiple sclerosis
- Assessing new options for lupus, rheumatoid arthritis, and juvenile arthritis
- Studying treatments that may improve symptoms in myasthenia gravis
Research in this area combines symptom control with the search for safer, more durable treatment strategies.
Gastroenterology and Liver Disease
The site is active in digestive system diseases and liver-related research, with studies in Crohn's disease, ulcerative colitis, pouchitis, esophageal disorders, hepatocellular carcinoma, and biliary tract cancer. These trials are mainly aimed at improving disease control, supporting remission, and evaluating new treatment approaches for both inflammatory and malignant conditions of the gastrointestinal tract.
- Testing therapies for inflammatory bowel disease and chronic pouchitis
- Studying treatments for liver and biliary cancers
- Evaluating options for esophageal and gastric cancers
This area shows a strong mix of cancer research and chronic digestive disease management.
Neurology and Neurodegenerative Disorders
Clinical trials also address nervous system diseases, including Parkinson's disease, Alzheimer’s disease, amyotrophic lateral sclerosis, epilepsy, and Lewy body dementia. The main goal is to evaluate therapies that may slow progression, improve daily functioning, or ease symptoms in conditions with major long-term impact on patients and families.
- Investigating treatments for movement disorders and cognitive decline
- Studying therapies for ALS and refractory epilepsy
- Assessing new approaches for dementia-related symptoms
This research supports both symptom relief and disease-modifying strategies in complex neurological conditions.
Dermatology, Allergy, and Musculoskeletal Care
Another important research theme includes skin and connective tissue diseases, musculoskeletal diseases, and related inflammatory disorders such as atopic dermatitis, psoriasis, hidradenitis suppurativa, prurigo nodularis, and psoriatic arthritis. Trials in this group are focused on reducing inflammation, improving skin symptoms, and helping patients achieve better day-to-day quality of life.
- Evaluating new treatments for chronic inflammatory skin diseases
- Studying therapies for psoriatic and rheumatologic conditions
- Testing approaches to improve long-term symptom control
The research portfolio here reflects a strong interest in immune-driven skin and joint disease.
Kidney, Metabolic, and Cardiovascular Research
The site also runs trials in nutritional and metabolic diseases, cardiovascular diseases, and kidney disease, including chronic kidney disease, immunoglobulin A nephropathy, type 2 diabetes, hypertension, and myocardial infarction. These studies are designed to slow disease progression, reduce complications, and evaluate whether new therapies can improve long-term health outcomes.
- Studying treatments to protect kidney function and delay progression
- Evaluating therapies for diabetes and high blood pressure
- Assessing cardiovascular risk reduction strategies
This area adds an important chronic disease dimension to the site’s broader clinical trial program.
Eye Diseases and Rare Conditions
A smaller but notable set of studies focuses on eye diseases and other rare disorders, including geographic atrophy, age-related macular degeneration, retinitis pigmentosa, and inherited syndromes such as neurofibromatosis type 1 and Turner syndrome. The purpose of these trials is to improve diagnosis, preserve function, and explore innovative treatments for conditions with limited options.
- Testing therapies for degenerative retinal disease
- Studying rare genetic and developmental disorders
- Exploring approaches that may preserve vision or function
These studies highlight the site’s involvement in specialized research beyond common adult diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 21 therapeutic areas and 15 of 395 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 368 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 88 by active trials.
lock +87 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB15trials
lock +49 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli
lock Showing 1 of 283 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 395 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 23 | Unknown | 2016-11-07 | 2026-07-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.